Literature DB >> 33094475

Trehalose Ameliorates Seizure Susceptibility in Lafora Disease Mouse Models by Suppressing Neuroinflammation and Endoplasmic Reticulum Stress.

Priyanka Sinha1, Bhupender Verma1, Subramaniam Ganesh2,3.   

Abstract

Lafora disease (LD) is one of the progressive and fatal forms of a neurodegenerative disorder and is characterized by teenage-onset myoclonic seizures. Neuropathological changes in LD include the formation of abnormal glycogen as Lafora bodies, gliosis, and neuroinflammation. LD is caused by defects in the gene coding for phosphatase (laforin) or ubiquitin ligase (malin). Mouse models of LD, developed by targeted disruption of these two genes, develop most symptoms of LD and show increased susceptibility to induced seizures. Studies on mouse models also suggest that defective autophagy might contribute to LD etiology. In an attempt to understand the specific role of autophagy in LD pathogenesis, in this study, we fed LD animals with trehalose, an inducer of autophagy, for 3 months and looked at its effect on the neuropathology and seizure susceptibility. We demonstrate here that trehalose ameliorates gliosis, neuroinflammation, and endoplasmic reticulum stress and reduces susceptibility to induced seizures in LD animals. However, trehalose did not affect the formation of Lafora bodies, suggesting the epileptic phenotype in LD could be either secondary to or independent of Lafora bodies. Taken together, our results suggest that autophagy inducers can be considered as potential therapeutic molecules for Lafora disease.

Entities:  

Keywords:  Autophagy; Carbohydrate; Chemical chaperone; Epilepsy; Neuroinflammation

Year:  2020        PMID: 33094475     DOI: 10.1007/s12035-020-02170-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  73 in total

1.  Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.

Authors:  Shweta Singh; Toshimitsu Suzuki; Akira Uchiyama; Satoko Kumada; Nobuko Moriyama; Shinichi Hirose; Yukitoshi Takahashi; Hideo Sugie; Koichi Mizoguchi; Yushi Inoue; Kazue Kimura; Yukio Sawaishi; Kazuhiro Yamakawa; Subramaniam Ganesh
Journal:  J Hum Genet       Date:  2005-07-15       Impact factor: 3.172

2.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.

Authors:  Matthew S Gentry; Carolyn A Worby; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-01       Impact factor: 11.205

Review 3.  New discoveries in progressive myoclonus epilepsies: a clinical outlook.

Authors:  Shweta Bhat; Subramaniam Ganesh
Journal:  Expert Rev Neurother       Date:  2018-08-09       Impact factor: 4.618

Review 4.  Lafora disease.

Authors:  Julie Turnbull; Erica Tiberia; Pasquale Striano; Pierre Genton; Stirling Carpenter; Cameron A Ackerley; Berge A Minassian
Journal:  Epileptic Disord       Date:  2016-09-01       Impact factor: 1.819

5.  Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice.

Authors:  Subramaniam Ganesh; Antonio V Delgado-Escueta; Toshiro Sakamoto; Maria Rosa Avila; Jesus Machado-Salas; Yoshinobu Hoshii; Takumi Akagi; Hiroshi Gomi; Toshimitsu Suzuki; Kenji Amano; Kishan Lal Agarwala; Yuki Hasegawa; Dong-Sheng Bai; Tokuhiro Ishihara; Tsutomu Hashikawa; Shigeyoshi Itohara; Eain M Cornford; Hiroaki Niki; Kazuhiro Yamakawa
Journal:  Hum Mol Genet       Date:  2002-05-15       Impact factor: 6.150

6.  Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes.

Authors:  S Ganesh; K L Agarwala; K Ueda; T Akagi; K Shoda; T Usui; T Hashikawa; H Osada; A V Delgado-Escueta; K Yamakawa
Journal:  Hum Mol Genet       Date:  2000-09-22       Impact factor: 6.150

7.  Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy.

Authors:  B A Minassian; J R Lee; J A Herbrick; J Huizenga; S Soder; A J Mungall; I Dunham; R Gardner; C Y Fong; S Carpenter; L Jardim; P Satishchandra; E Andermann; O C Snead; I Lopes-Cendes; L C Tsui; A V Delgado-Escueta; G A Rouleau; S W Scherer
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

8.  Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo.

Authors:  Vincent S Tagliabracci; Julie Turnbull; Wei Wang; Jean-Marie Girard; Xiaochu Zhao; Alexander V Skurat; Antonio V Delgado-Escueta; Berge A Minassian; Anna A Depaoli-Roach; Peter J Roach
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-26       Impact factor: 11.205

9.  Typical progression of myoclonic epilepsy of the Lafora type: a case report.

Authors:  Pasquale Striano; Federico Zara; Julie Turnbull; Jean-Marie Girard; Cameron A Ackerley; Mariarosaria Cervasio; Gaetano De Rosa; Maria Laura Del Basso-De Caro; Salvatore Striano; Berge A Minassian
Journal:  Nat Clin Pract Neurol       Date:  2008-02

10.  Mutations in NHLRC1 cause progressive myoclonus epilepsy.

Authors:  Elayne M Chan; Edwin J Young; Leonarda Ianzano; Iulia Munteanu; Xiaochu Zhao; Constantine C Christopoulos; Giuliano Avanzini; Maurizio Elia; Cameron A Ackerley; Nebojsa J Jovic; Saeed Bohlega; Eva Andermann; Guy A Rouleau; Antonio V Delgado-Escueta; Berge A Minassian; Stephen W Scherer
Journal:  Nat Genet       Date:  2003-09-07       Impact factor: 38.330

View more
  6 in total

1.  Age-Dependent Reduction in the Expression Levels of Genes Involved in Progressive Myoclonus Epilepsy Correlates with Increased Neuroinflammation and Seizure Susceptibility in Mouse Models.

Authors:  Priyanka Sinha; Bhupender Verma; Subramaniam Ganesh
Journal:  Mol Neurobiol       Date:  2022-06-22       Impact factor: 5.682

2.  Cognitive Deficits Found in a Pro-inflammatory State are Independent of ERK1/2 Signaling in the Murine Brain Hippocampus Treated with Shiga Toxin 2 from Enterohemorrhagic Escherichia coli.

Authors:  Clara Berdasco; Alipio Pinto; Mariano G Blake; Fernando Correa; Nadia A Longo Carbajosa; Ana B Celi; Patricia A Geoghegan; Adriana Cangelosi; Myriam Nuñez; Mariela M Gironacci; Jorge Goldstein
Journal:  Cell Mol Neurobiol       Date:  2022-10-13       Impact factor: 4.231

3.  Trehalose Treatment in Zebrafish Model of Lafora Disease.

Authors:  Stefania Della Vecchia; Asahi Ogi; Rosario Licitra; Francesca Abramo; Gabriele Nardi; Serena Mero; Silvia Landi; Roberta Battini; Federico Sicca; Gian Michele Ratto; Filippo Maria Santorelli; Maria Marchese
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

4.  Targeting Gys1 with AAV-SaCas9 Decreases Pathogenic Polyglucosan Bodies and Neuroinflammation in Adult Polyglucosan Body and Lafora Disease Mouse Models.

Authors:  Emrah Gumusgoz; Dikran R Guisso; Sahba Kasiri; Jun Wu; Matthew Dear; Brandy Verhalen; Silvia Nitschke; Sharmistha Mitra; Felix Nitschke; Berge A Minassian
Journal:  Neurotherapeutics       Date:  2021-04-08       Impact factor: 7.620

5.  Autophagy protein NRBF2 attenuates endoplasmic reticulum stress-associated neuroinflammation and oxidative stress via promoting autophagosome maturation by interacting with Rab7 after SAH.

Authors:  Hanhai Zeng; Huaijun Chen; Min Li; Jianfeng Zhuang; Yucong Peng; Hang Zhou; Chaoran Xu; Qian Yu; Xiongjie Fu; Shenglong Cao; Jing Cai; Feng Yan; Gao Chen
Journal:  J Neuroinflammation       Date:  2021-09-16       Impact factor: 8.322

Review 6.  Lafora disease: Current biology and therapeutic approaches.

Authors:  S Mitra; E Gumusgoz; B A Minassian
Journal:  Rev Neurol (Paris)       Date:  2021-07-21       Impact factor: 4.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.